<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lemoine J</submitter><funding>Telethon</funding><funding>AFM-Téléthon</funding><funding>AFM-Téléthon (French Muscular Dystrophy Association)</funding><pagination>21238</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11390959</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Duchenne Muscular dystrophy (DMD), a yet-incurable X-linked recessive disorder that results in muscle wasting and loss of ambulation is due to mutations in the dystrophin gene. Exonic duplications of dystrophin gene are a common type of mutations found in DMD patients. In this study, we utilized a single guide RNA CRISPR strategy targeting intronic regions to delete the extra duplicated regions in patient myogenic cells carrying duplication of exon 2, exons 2-9, and exons 8-9 in the DMD gene. Immunostaining on CRISPR-corrected derived myotubes demonstrated the rescue of dystrophin protein. Subsequent RNA sequencing of the DMD cells indicated rescue of genes of dystrophin related pathways. Examination of predicted close-match off-targets evidenced no aberrant gene editing at these loci. Here, we further demonstrate the efficiency of a single guide CRISPR strategy capable of deleting multi-exon duplications in the DMD gene without significant off target effect. Our study contributes valuable insights into the safety and efficacy of using single guide CRISPR strategy as a potential therapeutic approach for DMD patients with duplications of variable size.</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.</pubmed_title><pmcid>PMC11390959</pmcid><funding_grant_id>GTB12001</funding_grant_id><funding_grant_id>23853</funding_grant_id><pubmed_authors>Dorval A</pubmed_authors><pubmed_authors>Bovolenta M</pubmed_authors><pubmed_authors>Richard I</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Corre G</pubmed_authors><pubmed_authors>Dubois A</pubmed_authors><pubmed_authors>Warthi G</pubmed_authors><pubmed_authors>Lemoine J</pubmed_authors><pubmed_authors>Mamchaoui K</pubmed_authors><pubmed_authors>Jaber A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.</name><description>Duchenne Muscular dystrophy (DMD), a yet-incurable X-linked recessive disorder that results in muscle wasting and loss of ambulation is due to mutations in the dystrophin gene. Exonic duplications of dystrophin gene are a common type of mutations found in DMD patients. In this study, we utilized a single guide RNA CRISPR strategy targeting intronic regions to delete the extra duplicated regions in patient myogenic cells carrying duplication of exon 2, exons 2-9, and exons 8-9 in the DMD gene. Immunostaining on CRISPR-corrected derived myotubes demonstrated the rescue of dystrophin protein. Subsequent RNA sequencing of the DMD cells indicated rescue of genes of dystrophin related pathways. Examination of predicted close-match off-targets evidenced no aberrant gene editing at these loci. Here, we further demonstrate the efficiency of a single guide CRISPR strategy capable of deleting multi-exon duplications in the DMD gene without significant off target effect. Our study contributes valuable insights into the safety and efficacy of using single guide CRISPR strategy as a potential therapeutic approach for DMD patients with duplications of variable size.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T23:24:22.63Z</modification><creation>2025-04-07T00:02:00.437Z</creation></dates><accession>S-EPMC11390959</accession><cross_references><pubmed>39261505</pubmed><doi>10.1038/s41598-024-70075-5</doi></cross_references></HashMap>